The progress of postapproval clinical studies on Sabin IPV

References

• World Health Organization. Polio eradication & endgame strategic plan 2013-2018. Glob Polio Erad Initiat Work Draft 2013;23:1–99.
   Google Scholar
• Shimizu H. Development and introduction of inactivated poliovirus vaccines derived from Sabin strains in Japan. Vaccine. 2016;34:1975–85. doi:10.1016/j.vaccine.2014.11.015.
   PubMed Web of Science ®Google Scholar
• Okayasu H, Sein C, Hamidi A, Bakker WA, Sutter RW. Development of inactivated poliovirus vaccine from Sabin strains: a progress report. Biologicals. 2016;44(6):581–87. doi:10.1016/j.biologicals.2016.08.005.
   PubMed Web of Science ®Google Scholar
• He H, Wang Y, Deng X, Yue C, Tang X, Li Y, Liu Y, Yin Z, Zhang G, Chen Z, et al. Immunogenicity of three sequential schedules with Sabin inactivated poliovirus vaccine and bivalent oral poliovirus vaccine in Zhejiang, China: an open-label, randomised, controlled trial. Lancet Infect Dis. 2020;20(9):1071–79. doi:10.1016/S1473-3099(19)30738-8.
   PubMed Web of Science ®Google Scholar
• Zhao T, Mo Z, Ying Z, Huang T, Che Y, Li G, Yang X, Sun M, Jiang L, Shi L, et al. Post hoc analysis of two clinical trials to compare the immunogenicity and safety of different polio immunization schedules in Chinese infants. Ann Transl Med. 2021;9(3):253. doi:10.21037/atm-20-2537.
   PubMed Web of Science ®Google Scholar
• Yan S, Chen H, Zhang Z, Chang S, Xiao Y, Luo L, Zhang Z, Sun L, Chen X, Yang Y, et al. Immunogenicity and safety of different sequential schedules of Sabin strain-based inactivated poliovirus vaccination: a randomized, controlled, open-label, phase IV clinical trial in China. Vaccine. 2020;38(40):6274–79. doi:10.1016/j.vaccine.2020.07.042.
   PubMed Web of Science ®Google Scholar
• Wang Q, Zhang Y, Xu J. [Immunogenicity of sequential polio vaccination schedules that use inactivated polio vaccine as the first dose]. Chin J Vacc Immun. 2019;25(4):378–82.
   Google Scholar
• Huang Z, Sun X, Liu J, Li Z, Ren J, Wu L, Hu JY, Zhang JN. [Observation on safety of sequential vaccination schedule of different strain inactivated poliovirus vaccines]. Zhonghua Liu Xing Bing Xue Za Zhi. 2019;40(5):565–70. doi:10.3760/cma.j.0254-6450.2019.05.014.
   PubMedGoogle Scholar
• Fu S, Lin L, Cao F, Tian X, Chen T, Chen C, et al. [Comparison of immunization safety of 4 kinds of polio vaccines in Jilin province]. Chin J Vacc Immun. 2017;23(4):379–82.
   Google Scholar
• Xiao S, Yang T, Fei Y, Deng P, Yang L. [Basic immune effect of sequential immunization with oral live attenuated vaccine and inactivated poliomyelitis vaccine]. Chin J Biol. 2020;33(07):809–12.
   Google Scholar
• Shi X, Liu L, Zhou L, Zhou L. [Evaluation on effect of sequential immunization with inactivated poliovirus vaccine and oral live attenuated poliomyelitis vaccine]. Chin J Biol. 2018;31(5):519–22.
   Google Scholar
• Xiao S, Liu Y, Li G, Lin L. [Immunogenicity after sequential program by Sabin strain inactivated poliovirus vaccine instead of attenuated live vaccine in Meizhou City]. Occup Health. 2018;34(14):1949–51.
   Google Scholar
• Zhang J, Zhu Y, Xu X, Liu S, Wang J, Cong Y, et al. [Immunogenicity of two sequential primary immunization schedules with inactivated poliovirus vaccine and bivalent oral poliomyelitis attenuated live vaccine]. Chin J Biol. 2020;26(3):265–68.
   Google Scholar
• Ma M, G X, Yang L. [Immunogenicity and safety of sequential schedules of Sabin inactivated poliovirus vaccine with two dosage forms of bivalent oral poliovirus vaccines]. Chin General Nursing. 2020;18(25):3341–43.
   Google Scholar
• Shi X, Zhou L, Zhou L, Liu L. [Safety of domestic Sabin strain inactivated poliovirus vaccine]. Chin J Vacc Immun. 2017;8(4):383–86.
   Google Scholar
• Liao G, Li R, Li C, Sun M, Jiang S, Li Y, Mo Z, Xia J, Xie Z, Che Y, et al. Phase 3 trial of a Sabin strain-based inactivated poliovirus vaccine. J Infect Dis. 2016;214:1728–34. doi:10.1093/infdis/jiw433.
   PubMed Web of Science ®Google Scholar
• Jiang R, Liu X, Sun X, Wang J, Huang Z, Li C, Li Z, Zhou J, Pu Y, Ying Z, et al. Immunogenicity and safety of the inactivated poliomyelitis vaccine made from Sabin strains in a phase IV clinical trial for the vaccination of a large population. Vaccine. 2021;39(9):1463–71. doi:10.1016/j.vaccine.2021.01.027.
   PubMed Web of Science ®Google Scholar
• Hotta C, Ogawa T, Shirasawa H. Surveillance of immunity acquired from poliovirus immunization including vaccination with the Sabin strain-derived inactivated vaccine. Hum Vaccin Immunother. 2019;15:1154–59. doi:10.1080/21645515.2019.1572408.
   PubMed Web of Science ®Google Scholar
• Satoh H, Tanaka-Taya K, Shimizu H, Goto A, Tanaka S, Nakano T, Hotta C, Okazaki T, Itamochi M, Ito M, et al. Polio vaccination coverage and seroprevalence of poliovirus antibodies after the introduction of inactivated poliovirus vaccines for routine immunization in Japan. Vaccine. 2019;37:1964–71. doi:10.1016/j.vaccine.2019.02.034.
   PubMed Web of Science ®Google Scholar
• Crawt L, Atkinson E, Tedcastle A, Pegg E, Ipvsg M, Minor P, Cooper G, Rigsby P, Martin J. Differences in antigenic structure of inactivated polio vaccines made from sabin live-attenuated and wild-type poliovirus strains: impact on vaccine potency assays. J Infect Dis. 2020;221:544–52. doi:10.1093/infdis/jiz076.
   PubMed Web of Science ®Google Scholar
• Zipursky S, Patel M, Farrell M, Gonzalez AR, Kachra T, Folly Y, Kurji F, Veira CL, Wootton E, Hampton LM, et al. Lessons learned from managing the planning and implementation of inactivated polio vaccine introduction in support of the polio endgame. J Infect Dis. 2017;216:S15–S23. doi:10.1093/infdis/jix185.
   PubMed Web of Science ®Google Scholar
• Sun M, Li C, Xu W, Liao G, Li R, Zhou J, Li Y, Cai W, Yan D, Che Y, et al. Immune serum from sabin inactivated poliovirus vaccine immunization neutralizes multiple individual wild and vaccine-derived polioviruses. Clin Infect Dis. 2017;64(10):1317–25. doi:10.1093/cid/cix110.
   PubMed Web of Science ®Google Scholar